The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

Author： Sun Jong-Mu   Won Young-Woong   Kim Seung   Kim Jung   Choi Yoon-La   Lee Jeeyun   Park Yeon   Ahn Jin   Park Keunchil   Ahn Myung-Ju  

Publisher： Springer Publishing Company

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.137, Iss.4, 2011-04, pp. : 687-694

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite

Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

By Chu Huili   Zhong Chen   Xue Guoliang   Liang Xiuju   Wang Jun   Liu Yingxin   Zhao Shiwei   Zhou Qian   Bi Jingwang  

Oncology Reports, Vol. 30, Iss. 5, 2013-11 ,pp. : 2311-2315

Spandidos Publications

Access to resources Recommend Favorite

A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1040-1048

Spandidos Publications

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite